The Effect of Aspirin on the Antiproteinuric Properties of Enalapril in Microalbuminuric Type 2 Diabetic Patients
A randomized, double-blind, placebo-controlled study
- Eduardo G. Camargo, MD,
- Letícia S. Weinert, MD,
- Joel Lavinsky, MD,
- Jorge L. Gross, MD and
- Sandra P. Silveiro, MD
- From the Endocrine Division, Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil
- Address correspondence to Sandra P. Silveiro, Serviço Endocrinologia, Hospital de Clínicas de Porto Alegre, Ramiro Barcelos, 2350, Porto Alegre, Brazil. E-mail: sandrasilveiro{at}terra.com.br
The concomitant use of angiotensin-converting enzyme inhibitors (ACEIs) and aspirin is recommended for any diabetic patient with microalbuminuria or macroalbuminuria because these drugs result in renal and cardiovascular benefits (1,2). However, a putative pharmacological interaction between these drugs is plausible, through their opposite effects on vasodilator prostaglandins (3). Therefore, the aim of this study was to analyze the possible interference of intermediate-dose aspirin (300 mg/day) on urinary albumin excretion (UAE) reduction properties of enalapril in microalbuminuric type 2 diabetic patients.
In this randomized, crossover, double-blind, placebo-controlled …
